← Leaderboards
Oleg Shinkazh
Chromatan Corporation
$8,029,352
Attributed
$8,029,352
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,029,352 · 4
By mechanism
R44$7,846,352 · 3
R43$183,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionMonoclonal AntibodiesTechnologyCostSmall Business Innovation Research GrantOperationPlant ResinsChromatographyProteinsScale UpCommercializationProductivityCyclic GmpPerformancePressureValidationNext GenerationTherapeutic ProteinBioreactorsColumn ChromatographyFundingMalignant NeoplasmsDesignGrant
Grant awards (14)
Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)$695,448
R44 · FY2025 · GM · contact PI
Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)$1,304,417
R44 · FY2024 · GM · contact PI
Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)$214,459
R44 · FY2024 · GM · contact PI
Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$707,318
R44 · FY2023 · GM · contact PI
Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$503,755
R44 · FY2023 · GM · contact PI
Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$1,284,233
R44 · FY2022 · GM · contact PI
Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$540,290
R44 · FY2018 · GM · contact PI
Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$255,778
R44 · FY2018 · GM · contact PI
Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$941,104
R44 · FY2017 · GM · contact PI
Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$222,379
R44 · FY2016 · GM · contact PI
Phase II Commercialization of Continuous Countercurrent Tangential Chromatography$407,095
R44 · FY2014 · GM · contact PI
Phase II Commercialization of Continuous Countercurrent Tangential Chromatography$175,000
R44 · FY2014 · GM · contact PI
Phase II Commercialization of Continuous Countercurrent Tangential Chromatography$595,076
R44 · FY2013 · GM · contact PI
Continuous Countercurrent Tangential Chromatography$183,000
R43 · FY2011 · RR · contact PI